SMEP
17.1.2024 10:57:28 CET | Business Wire | Press release
Saudi Arabia reinforced its call for an immediate ceasefire in Gaza, and an end to the spiraling volatility in the Red Sea, today at the World Economic Forum (WEF) Annual Meeting 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116473725/en/
Saudi Arabia reiterates call for immediate ceasefire in Gaza at the World Economic Forum Annual Meeting 2024 (Photo: AETOSWire)
Speaking at a session on ‘Securing an Insecure World’, Saudi Arabia’s Minister of Foreign Affairs, His Highness Prince Faisal bin Farhan bin Abdullah, said: “We need to focus on the immediate crisis which is the suffering that is happening in Gaza.
“The international community has been moving more in the direction that we have called for since the beginning, which is a ceasefire and more humanitarian aid. But we need to do more. We agree that regional peace includes peace for Israel, but that can only happen through peace for the Palestinians, through a Palestinian state.”
On the escalating volatility in the Red Sea, His Highness added: “Freedom of navigation in the Red Sea is something that impacts all of us, and the priority needs to be de-escalation.”
During a panel session on “Frictionless Services”, His Excellency Dr. Majid A. Alkassabi, Minister of Commerce, described the speed and scale of Saudi Arabia’s economic diversification, saying The Kingdom “has revamped over 200 laws and bylaws to make the business environment attractive.”
His Excellency Adel A. Aljubeir, Minister of State for Foreign Affairs, Member of the Council of Ministers, and Envoy for Climate, Member of the Council of Ministers and Envoy for Climate Affairs reiterated the need for substantive global collaboration to tackle the climate crisis, saying, “unless we work together, we are going to achieve nothing,” in a session as part of the new Saudi House: Bold Visions Series – the Kingdom’s pavilion connecting policymakers and innovators.
In ‘Gulf Economies: All In,’ His Excellency Khalid A. Al Falih, Minister of Investment, shared his optimistic outlook for the Gulf, noting how “the GCC is attracting FDI at more than twice the average rate than around the world when you compare it and normalize it for GDP. We believe we are at inflection point of increase of FDI, as we have seen in Saudi Arabia.”
In a session on ‘Regulating Non-Banks’, His Excellency Mohammed Aljadaan, Minister of Finance, warned governments not to “kill innovation” and deprive the private sector from investment opportunities by applying blanket regulatory frameworks to banks and non-regulated financial institutions, alike.
In a session on ‘AI: The Great Equaliser’, His Excellency Abdullah A. Alswaha, Minister of Communications and Information Technology, said the Kingdom’s consistency on being “pro-innovation, pro-partnership” has harnessed emerging technologies like Generative AI to build a human-centric future.
His Excellency Bandar I. Alkhorayef, Minister of Industry and Mineral Resources, highlighted Saudi Arabia’s “three dimensional” policy approach to building industrial capabilities and creating an investor-friendly environment to unlock the untapped potential of Saudi Arabia’s vast mineral assets.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116473725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom